Researchers have discovered a mutation in DDR2 gene that helps to identify which patients with squamous cell lung cancer will respond to a leukemia drug called dasatinib.

Using standard genetic sequencing techniques, Meyerson and colleagues identified mutations in the DDR2 kinase gene in about 3 percent of squamous cell lung cancers and cell lines.
Furthermore, they found that tumor cells with these DDR2 mutations responded to treatment with dasatinib.
A patient whose cancer carried a DDR2 mutation also showed a clinical response to dasatinib.
"Dasatinib is an existing therapy for chronic myelogenous leukemia with a long history and a strong safety profile," said Meyerson.
"The results of this study clearly encourage a clinical trial to test dasatinib in the setting of squamous cell lung cancer," he added.
Advertisements
Source-ANI